ZURA News & Events

Tenaya Therapeutics (TNYA) announced the appointment of Eric Hyllengren as CFO, effective July 13. In this role, he will oversee financial strategy, capital allocation, investor relations and corporate development. He most recently served as CFO and executive VP of Zura Bio (ZURA).

Cash and cash equivalents were $225.6M as of March 31, 2026. Consistent with prior guidance and inclusive of the planned third-indication study, Zura continues to expect its existing cash to fund planned operations through at least the end of 2028.

Zura Bio announced several tibulizumab program updates. Zura has completed enrollment of the Phase 2 TibuSHIELD trial of tibulizumab in adults with HS. The TibuSHIELD trial exceeded the target enrollment, with 247 participants enrolled. Zura remains on track to complete enrollment of the Phase 2 TibuSURE trial of tibulizumab in adults with early diffuse cutaneous SSc in early July. The TibuSURE trial has already exceeded the target enrollment of 80 participants. Exceeding enrollment targets in both TibuSHIELD and TibuSURE reflects the significant unmet need facing patients with HS and SSc. Topline data from TibuSHIELD are expected in the fourth quarter of 2026. Topline data from TibuSURE are expected in H1 2027. Building on tibulizumab's bispecific mechanism targeting both interleukin-17 and B cell activating factor, Zura plans to initiate a Phase 2 study in a third immune-mediated indication by year end 2026. Indication expansion of tibulizumab reflects Zura's belief in the broad potential of IL-17 and BAFF dual pathway inhibition across immune-mediated diseases. Zura plans to announce the new indication prior to study initiation.